• Study Resource
  • Explore Categories
    • Arts & Humanities
    • Business
    • Engineering & Technology
    • Foreign Language
    • History
    • Math
    • Science
    • Social Science

    Top subcategories

    • Advanced Math
    • Algebra
    • Basic Math
    • Calculus
    • Geometry
    • Linear Algebra
    • Pre-Algebra
    • Pre-Calculus
    • Statistics And Probability
    • Trigonometry
    • other →

    Top subcategories

    • Astronomy
    • Astrophysics
    • Biology
    • Chemistry
    • Earth Science
    • Environmental Science
    • Health Science
    • Physics
    • other →

    Top subcategories

    • Anthropology
    • Law
    • Political Science
    • Psychology
    • Sociology
    • other →

    Top subcategories

    • Accounting
    • Economics
    • Finance
    • Management
    • other →

    Top subcategories

    • Aerospace Engineering
    • Bioengineering
    • Chemical Engineering
    • Civil Engineering
    • Computer Science
    • Electrical Engineering
    • Industrial Engineering
    • Mechanical Engineering
    • Web Design
    • other →

    Top subcategories

    • Architecture
    • Communications
    • English
    • Gender Studies
    • Music
    • Performing Arts
    • Philosophy
    • Religious Studies
    • Writing
    • other →

    Top subcategories

    • Ancient History
    • European History
    • US History
    • World History
    • other →

    Top subcategories

    • Croatian
    • Czech
    • Finnish
    • Greek
    • Hindi
    • Japanese
    • Korean
    • Persian
    • Swedish
    • Turkish
    • other →
 
Profile Documents Logout
Upload
Statement on the use of EFV in children less than 3 years of age
Statement on the use of EFV in children less than 3 years of age

... Statement on the use of Efavirenz in children less than 3 years of age On 02 May 2013, the US Food and Drug Administration (FDA) expanded the indication for efavirenz (EFV) to include paediatric patients at least three months old and weighing at least 3.5 kg. Historically efavirenz has not been used ...
Contrast Agent and Radiopharmaceutical Billing Codes Hospital
Contrast Agent and Radiopharmaceutical Billing Codes Hospital

... regardless of whether the items are paid separately or packaged, using the correct HCPCS codes for the items used. It is also of great importance that hospitals billing for these products make certain that the reported units of service of the reported HCPCS codes are consistent with the quantity of ...
ICH, WHO AND SUPAC GUIDELINES  ICH GUIDELINES
ICH, WHO AND SUPAC GUIDELINES ICH GUIDELINES

... Brussels. Representatives of the regulatory agencies and industry associations of Europe, Japan and the USA met, primarily, to plan an International Conference but the meeting also discussed the wider implications and terms of reference of ICH. The ICH Steering Committee which was established at tha ...
Protocol S1.
Protocol S1.

... tested in the combination with CQ. This drug combination was found to be safe even in G6PD deficient adults and children (Mandi et al. 2005, Meissner et al. 2005). The combination was however not sufficiently effective against uncomplicated falciparum malaria in young children when given at a dose o ...
ketorolac tromethamine utilization management criteria
ketorolac tromethamine utilization management criteria

... Quantity limitations are based on restrictions placed by the FDA in the package inserts for Ketorolac: Ketorolac tablets are only indicated as follow up to ketorolac injection: Combined use beyond 5 days increases the risk of serious adverse events such as peptic ulcer and gastrointestinal bleeding/ ...
bureau of tenncare - Magellan Health Services || TennCare Portal
bureau of tenncare - Magellan Health Services || TennCare Portal

... TennCare is continuing the process of reviewing all covered drug classes. Changes to the PDL may occur as new classes are reviewed and previously reviewed classes are revisited. As a result of these changes, some medications your patients are now taking may be considered non-preferred agents in the ...
3% annual mortality rate
3% annual mortality rate

... Unmet Need of Chronic Angina  Angina continues in many patients despite medical therapy and mechanical revascularization  The personal burden can deprive many patients of their functional independence, forcing them to downsize their lives  The economic toll of angina places a huge burden on pati ...
Treatment Options for Wet Macular Degeneration (MD)
Treatment Options for Wet Macular Degeneration (MD)

... TREATMENTS PROVEN TO BE EFFECTIVE BY CONTROLLED TRIALS but not yet published in peer review journals 1. Lucentis (ranibizumab) Lucentis is an anti-VEGF drug which is injected into the eye (into the vitreous) at 4 week intervals. The one year results have been reported and are soon to be published. T ...
USP`s Role in Patient Safety Goals: Objectives
USP`s Role in Patient Safety Goals: Objectives

... Because of concern with the quality of drug products on the market, in 1971, the USP and the FDA co-founded the Drug Product Problem Reporting Program (DPPR). This was a national program in which health professionals voluntarily reported problems and defects experienced with drug products marketed i ...
Guidance for timing of medication
Guidance for timing of medication

... advice should be sought from a prescriber or from a member of pharmacy staff. Consideration must always be given to the actual time of administration so that a sufficient time period occurs between doses, or the dose may have to be omitted. However, there are circumstances where a patient may not re ...
IMC Analysis Pfizer`s Zoloft 1 IMC ANALYSIS
IMC Analysis Pfizer`s Zoloft 1 IMC ANALYSIS

... promotional to inform healthcare professionals, payers and patients about benefits and risks of new treatments for diseases (Sen, 2001). As Zoloft was coming to an end on its patent the DDMAC requested that Pfizer immediately cease the dissemination of promotional materials for Zoloft before May 20, ...
Naturopathy Act, 2007 - O. Reg. 168/15
Naturopathy Act, 2007 - O. Reg. 168/15

... of the profession in this section and section 3 of this Regulation is authorized to perform the following controlled acts: 1. Administering a substance specified in Table 1 by inhalation to a patient, in accordance with any limitations respecting the substance set out in the Table. 2. Administering ...
Ethinylestradiol for the induction of delayed puberty
Ethinylestradiol for the induction of delayed puberty

... Specialist to detail below the action to be taken upon occurrence of a particular adverse event as appropriate. Most serious toxicity is seen with long-term use and may therefore present first to GPs. ...
effect of five alive juice on the dissolution and
effect of five alive juice on the dissolution and

... pumped back into the intestinal lumen from the gut wall by a P-glycoprotein transporter (P-gp). P-gp and CYP3A4 may therefore act in tandem as a barrier to drugs moving from the gut to the systemic circulation 11. Grape juice appears to selectively inhibit intestinal CYP3A4 isoenzyme expression 12. ...
Tetracycline group in children
Tetracycline group in children

... oral dose absorbed on an empty stomach is low for chlortetracyclines (30%); intermediate for oxytetracycline, demeclocycline, tetracycline (60% to 80%); and high for doxycycline (95%) and minocycline (100%). High lipid solubility of doxycycline and minocycline contribute to this. Food, including dai ...
Clinical Uses of Metronidazole in Paediatric Dentistry
Clinical Uses of Metronidazole in Paediatric Dentistry

... Metronidazole,l-(2-hydroxycthyl)-2-methyl-5nitroimidazole, which is a nitroheterocyclic compound ,is specifically antianaerobic in nature and has a broad spectrum of activity against protozoa and anaerobic bacteria.1 Metronidazole was introduced as an anti-trichomonal agent via classical pharmaco-ch ...
Motrin - Dilantin | Stevens-Johnson Syndrome Side Effects
Motrin - Dilantin | Stevens-Johnson Syndrome Side Effects

... L/kg while adults have a volume of approximately 0.12 L/kg. The clinical significance of these findings is unknown. Metabolism - Following oral administration, the majority of the dose was recovered in the urine within 24 hours as the hydroxy-(25%) and carboxypropyl-(37%) phenylpropionic acid metabo ...
Book Chapters, Monographs, Books
Book Chapters, Monographs, Books

... 41. Rotheram-Fuller, E., Shoptaw, S., Berman, S.M., London, E.D. (2004). Impaired performance in a test of decision-making by opiate-dependent tobacco smokers. Drug and Alcohol Dependence, 73(1):79-86. 42. Scott, R.L., Shoptaw, S. (2003). A pilot study of contextual and partner factors that contribu ...


... and mortality in public, affecting humans of all ages. About 20,000 deaths occur every year due to liver disorders.1 Some of the commonly known disorders are viral hepatitis, alcohol liver disease, non-alcoholic fatty liver disease, autoimmune liver disease. Liver is quantitatively the most importan ...
Double-blind, Randomized, Placebo-Controlled Trial of Varenicline
Double-blind, Randomized, Placebo-Controlled Trial of Varenicline

... Anecdotally, patients who were tremulous, or who had very advanced disease, did not appear to benefit as much, OR had the problematic side effect of weakness (1 patient, most severely affected) FA: very early patients often developed that “weakness”: due to spasiticity? While varenicline gets a bad ...
LSD Possession
LSD Possession

... LSD production reportedly is centered on the West Coast, particularly in San Francisco, northern California, the Pacific Northwest, and recently the Midwest. Since the 1960s, LSD has been manufactured illegally within the United States. LSD production is a time-consuming and complex procedure. Sever ...
An approach to bypass the blood brain barrier
An approach to bypass the blood brain barrier

... The olfactory epithelium is a gateway for substances entering the CNS and the peripheral circulation. The neural connections between the nasal mucosa and the brain provide a unique pathway for the non-invasive delivery of therapeutic agents to the CNS.9,11,26 The olfactory neural pathway provides bo ...
What are effective medication combinations for dyslipidemia?
What are effective medication combinations for dyslipidemia?

... effects for combined dyslipidemia (SOR: A). Most combination therapies increase the risk of intolerance or side effects, including myopathy. The statin/gemfibrozil combination has the highest risk of myopathy, whereas statin/ ezetimibe or statin/bile acid sequestrant have the ...
Nanotechnology in Drug Discovery-Development and
Nanotechnology in Drug Discovery-Development and

... and can be acted upon by a drug. • Target validation is crucial to help scientists avoid research paths that look promising, but ultimately lead to dead ends. • Researchers demonstrate that a particular target is relevant to the disease being studied through complicated experiments in both living an ...
Marijuana
Marijuana

... History of marijuana in medical field The use of marijuana in medicine can be traced as early as 2737 BC, during the reign of Chinese emperor, Shen Neng. The emperor use to prescribe marijuana tea as a method of treating gout malaria and rheumatism. It was from these uses that popularity of the drug ...
< 1 ... 170 171 172 173 174 175 176 177 178 ... 672 >

Prescription costs

Prescription costs are a common health care cost for many people and also the source of considerable economic hardship for some. These costs are sometimes referred to as out-of-pocket prescription costs, since for those with insurance, the total cost of their prescriptions may include expenses covered by a third party, such as an insurance company, as well as the individual. Out-of-pocket prescription costs include deductibles, co-payments, and upper limits in coverage.
  • studyres.com © 2026
  • DMCA
  • Privacy
  • Terms
  • Report